Wegovy Pill: The Complete Guide to Oral Semaglutide for Weight Loss

Wegovy pill was FDA approved on December 22, 2025. It is the first oral GLP-1 medication approved specifically for weight loss in adults, making it a significant option for people who want the clinical benefits of semaglutide without weekly injections.

Here is a practical guide to what it is, how to take it, and how it compares to other options.

What is the Wegovy pill?

Wegovy pill contains oral semaglutide 25 mg - the same active molecule as Wegovy injection and Ozempic, but formulated as a once-daily tablet. It is approved for:

• weight reduction in adults with obesity (BMI ≥ 30)
• weight reduction in adults who are overweight (BMI ≥ 27) with at least one weight-related health condition
• reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity or overweight and established heart disease

It is available in the United States through standard pharmacies, NovoCare direct pharmacy, and telehealth providers including Hims & Hers.

How does it work?

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut releases after eating, which:

• reduces appetite and food cravings
• slows gastric emptying (you feel full longer)
• improves insulin response
• signals the brain to reduce caloric intake

The oral formulation uses a co-formulation with a carrier molecule (SNAC) that helps semaglutide absorb through the stomach lining. This is why strict dosing rules are required.

How to take the Wegovy pill correctly

This is critical. Semaglutide does not absorb properly if taken incorrectly.

Rules for every dose:

1. Take on a completely empty stomach
2. Use no more than 120 ml (about half a cup) of plain water to swallow the tablet
3. Do not eat, drink anything other than water, or take other oral medications for at least 30 minutes after

Missing these rules significantly reduces how much semaglutide your body absorbs. This is the main practical difference from Orforglipron, which has no food restrictions.

Dosing schedule

Wegovy pill uses a gradual escalation to reduce gastrointestinal side effects:

Full maintenance dose is reached at approximately week 13.

What weight loss can you expect?

The OASIS 4 Phase 3 trial (64 weeks, 307 adults with obesity, no diabetes) showed:

• 16.6% average weight loss for patients who stayed on treatment
• 13.6% average weight loss in the real-world analysis
• 76% of patients achieved at least 5% weight loss vs 31% on placebo
• Baseline body weight: approximately 235 lbs (107 kg)

That translates to roughly 35–40 lbs average weight loss for patients at a typical starting weight who stay on the medication.

Side effects

Side effects are the same as with the injectable form:

• Nausea - most common, especially during the escalation phase
• Diarrhea
• Vomiting
• Constipation
• Fatigue

For most patients, these are mild to moderate and improve over time. The gradual escalation schedule is designed specifically to reduce early side effects.

Wegovy pill vs Wegovy injection

For patients who are comfortable with injections, the weekly shot may be easier to manage day-to-day because there are no morning dosing rules. For patients who want to avoid injections entirely, the pill is now a viable option.

Wegovy pill vs Orforglipron

Both are daily oral GLP-1 medications, but they differ in an important way.

Orforglipron (Eli Lilly, FDA filing pending) is a non-peptide small molecule - it does not require food restrictions. You can take it at any time, with or without food. The Wegovy pill requires fasting and a 30-minute wait.

In the ACHIEVE-3 head-to-head trial, orforglipron produced significantly more weight loss than a 14 mg dose of oral semaglutide in T2D patients. However, the Wegovy pill is approved at 25 mg, which is much higher than the 14 mg dose used in that comparison.

Tracking the Wegovy pill

Switching from an injection to a daily pill changes your tracking pattern. Instead of a weekly injection day as your anchor, you are logging a daily routine. The dosing rules (empty stomach, timing) are important to track consistently, especially during the escalation phase when missing doses can affect side effect patterns.

WeightEasy supports all semaglutide formulations and helps you track dose changes, side effects, and weight trends across the escalation period.

Final takeaway

Wegovy pill is a once-daily oral semaglutide approved in December 2025 for weight loss in adults with obesity. It delivers comparable weight loss to the weekly injection but requires strict morning dosing rules. It is a meaningful option for patients who prefer tablets over injections.

Consult your healthcare provider before starting any weight loss medication.

Sources

• FDA approval announcement: Wegovy Pill, December 22, 2025
• OASIS 4 trial: Wharton S, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393:1077-1087
• Novo Nordisk / Hims & Hers partnership announcement, March 9, 2026
• Wegovy FDA approval history: drugs.com/history/wegovy.html